Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells

Oncogene

Volumn 28, Issue 31, 2009, Pages 2784-2795

  Bauer, K ^a,b   Kretzschmar, A K ^a,f   Cvijic, H ^a   Blumert, C ^a   Loffler D ^a,b   Brocke Heidrich, K ^a,b   Schiene Fischer, C ^c   Fischer, G ^c   Sinz, A ^d   Clevenger, C V ^e   Horn, F ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c MAX PLANCK RESEARCH UNIT FOR ENZYMOLOGY OF PROTEIN FOLDING   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e NORTHWESTERN UNIVERSITY   (United States)

^f FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

Author keywords

Cyclophilin A; Cyclophilin B; Cyclosporine A; Interleukin 6; Multiple myeloma; Stat3

Indexed keywords

CYCLOPHILIN A; CYCLOPHILIN B; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 6; PEPTIDYLPROLYL ISOMERASE; STAT1 PROTEIN; STAT3 PROTEIN; TYROSINE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL CYCLE; CELL GROWTH; CELL NUCLEUS; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; FLUORESCENCE MICROSCOPY; GENE SILENCING; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MULTIPLE MYELOMA; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

APOPTOSIS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CYCLOPHILIN A; CYCLOPHILINS; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-6; LUCIFERASES; LUMINESCENT PROTEINS; MICROSCOPY, FLUORESCENCE; MULTIPLE MYELOMA; PHOSPHORYLATION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 68349148257     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.142     Document Type: Article

References (51)

1. Allain F, Denys A, Spik G. (1996). Cyclophilin B mediates cyclosporin A incorporation in human blood T-lymphocytes through the specific binding of complexed drug to the cell surface. Biochem J 317(Pt 2): 565-570.
2. Arevalo-Rodriguez M, Cardenas ME, Wu X, Hanes SD, Heitman J. (2000). Cyclophilin A and Essl interact with and regulate silencing by the Sin3-Rpd3 histone deacetylase. EMBO J 19: 3739-3749.
3. Bellido T, O'Brien CA, Roberson PK, Manolagas SC. (1998). Transcriptional activation of the p21(WAFl, CIPl, SDIl) gene by interleukin-6 type cytokines. A prerequisite for their pro- differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem 273: 21137-21144.
4. Billich A, Winkler G, Aschauer H, Rot A, Peichl P. (1997). Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J Exp Med 185: 975-980.
5. Brazin KN, Mallis RJ, Fulton DB, Andreotti AH. (2002). Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. Proc Natl Acad Sci USA 99: 1899-1904.
6. Brocke-Heidrich K, Ge B, Cvijic H, Pfeifer G, Löffler D, Henze C et al. (2006). BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 25: 7297-7304.
7. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Löffler D, Koczan D et al. (2004). Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 103: 242-251.
8. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. (1999). Stat3 as an oncogene. Cell 98: 295-303.
9. Brummelkamp TR, Bernards R, Agami R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553.
10. Bukrinsky MI. (2002). Cyclophilins: unexpected messengers in intercellular communications. Trends Immunol 23: 323-325.
11. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. (1999). Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115.
12. Choi KJ, Piao YJ, Lim MJ, Kim JH, Ha J, Choe W et al. (2007). Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res 67: 3654-3662.
13. Cui Y, Mirkia K, Florence Fu YH, Zhu L, Yokoyama KK, Chiu R. (2002). Interaction of the retinoblastoma gene product, RB, with cyclophilin A negatively affects cyclosporin-inhibited NFAT signaling. J Cell Biochem 86: 630-641.
14. De Ceuninck F, Allain F, Caliez A, Spik G, Vanhoutte PM. (2003). High binding capacity of cyclophilin B to chondrocyte heparan sulfate proteoglycans and its release from the cell surface by matrix metalloproteinases: possible role as a proinflammatory mediator in arthritis. Arthritis Rheum 48: 2197-2206.
15. Fang F, Flegler AJ, Du P, Lin S, Clevenger CV. (2009). Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. Am J Pathol 174: 297-308.
16. Gerhartz C, Heesel B, Sasse J, Hemmann U, Landgraf C, Schneider-Mergener J et al. (1996). Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J Biol Chem 271: 12991-12998.
17. Hodge DR, Hurt EM, Farrar WL. (2005). The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
18. Howard BA, Furumai R, Campa MJ, Rabbani ZN, Vujaskovic Z, Wang XF et al. (2005). Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res 65: 8853-8860.
19. Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E et al. (2004). Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 46: 313-323.
20. Ihling C, Berger K, Hofliger MM, Fuhrer D, Beck-Sickinger AG, Sinz A. (2003). Nano-high-performance liquid chromatography in combination with nano-electrospray ionization Fourier transform ion-cyclotron resonance mass spectrometry for proteome analysis. Rapid Commun Mass Spectrom 17: 1240-1246.
21. Jensen O, Shevchenko A, Mann M. (1997) In: Creighton TE (ed). Protein Structure, A Practical Approach. Oxford University Press: Oxford, UK, pp 48.
22. Kitahara K, Kawai S. (2007). Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 19: 238-245.
23. Kofron JL, Kuzmic P, Kishore V, Colon-Bonilla E, Rich DH. (1991). Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry 30: 6127-6134.
24. Kretzschmar AK, Dinger MC, Henze C, Brocke-Heidrich K, Horn F. (2004). Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells. Biochem J 377: 289-297.
25. Leverson JD, Ness SA. (1998). Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanism. Mol Cell 1: 203-211.
26. Löffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretzschmar AK et al. (2007). Interleukin-6- dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood.
27. Lufei C, Koh TH, Uchida T, Cao X. (2007). Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity. Oncogene 26: 7656-7664.
28. Lütticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A et al. (1994). Association of transcription factor APRF and protein kinase JAK1 with the IL-6 signal transducer gp130. Science 263: 89-92.
29. Mamane Y, Sharma S, Petropoulos L, Lin R, Hiscott J. (2000). Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52. Immunity 12: 129-140.
30. Mariller C, Allain F, Kouach M, Spik G. (1996). Evidence that human milk isolated cyclophilin B corresponds to a truncated form. Biochim Biophys Acta 1293: 31-38.
31. Obata Y, Yamamoto K, Miyazaki M, Shimotohno K, Kohno S, Matsuyama T. (2005). Role of cyclophilin B in activation of interferon regulatory factor-3. J Biol Chem 280: 18355-18360.
32. Peters M, Blinn G, Solem F, Fischer M, Meyer zum Buschenfelde KH, Rose-John S. (1998). in vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol 161: 3575-3581.
33. Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A et al. (2003). Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 278: 5794-5801.
34. Puthier D, Thabard W, Rapp M, Etrillard M, Harousseau J, Bataille R et al. (2001). Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule. Br J Haematol 112: 358-363.
35. Rawat R, Rainey GJ, Thompson CD, Frazier-Jessen MR, Brown RT, Nordan RP. (2000). Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas. Blood 96: 3514-3521.
36. Rycyzyn MA, Clevenger CV. (2002). The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci USA 99: 6790-6795.
37. Rycyzyn MA, Reilly SC, O'Malley K, Clevenger CV. (2000). Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. Mol Endocrinol 14: 1175-1186.
38. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G et al. (2003). Regulation of NF-kappaB signaling by Pinl-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 12: 1413-1426.
39. Schwarze MM, Hawley RG. (1995). Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated upregulation of bcl-xL. Cancer Res 55: 2262-2265.
40. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. (2004). Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64: 9018-9026.
41. Sherry B, Yarlett N, Strupp A, Cerami A. (1992). Identification of cyclophilin as a proinflammatory secretory product of lipopolysac-charide- activated macrophages. Proc Natl Acad Sci USA 89: 3511-3515.
42. Song J, Lu YC, Yokoyama K, Rossi J, Chiu R. (2004). Cyclophilin A is required for retinoic acid-induced neuronal differentiation in p19 cells. J Biol Chem 279: 24414-24419.
43. Syed F, Rycyzyn MA, Westgate L, Clevenger CV. (2003). A novel and functional interaction between cyclophilin A and prolactin receptor. Endocrine 20: 83-90.
44. Uittenbogaard A, Ying Y, Smart EJ. (1998). Characterization of a cytosolic heat-shock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. J Biol Chem 273: 6525-6532.
45. Wang P, Heitman J. (2005). The cyclophilins. Genome Biol 6: 226.
46. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y et al. (2005). Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 19: 111-122.
47. Wegenka UM, Buschmann J, Lütticken C, Heinrich PC, Horn F. (1993). Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 13: 276-288.
48. Yang Y, Lu N, Zhou J, Chen ZN, Zhu P. (2008). Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD 147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 47: 1299-1310.
49. Yuan J, Wegenka UM, Lütticken C, Buschmann J, Decker T, Schindler C et al. (1994). The signalling pathways of interleukin-6 and gamma interferon converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol Cell Biol 14: 1657-1668.
50. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S et al. (2002). The prolyl isomerase Pinl reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853-857.
51. Zheng J, Koblinski JE, Dutson LV, Feeney YB, Clevenger CV. (2008). Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res 68: 7769-7778.